EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinician awareness, testing, and treatment for lipoprotein(a): Results from a large US national survey

Nathan D Wong, Yihang Fan, Wenjun Fan, Jonathan H Ward, Belinda Schludi, Xingdi Hu

American Journal of Preventive Cardiology · 2026-02 · 25 · 101388

DOI: 10.1016/j.ajpc.2025.101388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Preventive Cardiology, 2026-02. Verfasst von Nathan D Wong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Mary and Steve Wen Cardiovascular Division and Center for Global Cardiometabolic Health and Nutrition, University of California, Irvine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharmaceuticals Corporation, University of California, Irvine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data are limited regarding national clinician awareness, testing, and treatment of lipoprotein(a) [Lp(a)]. We conducted a national survey of US clinicians to investigate these issues.

Methods

An internet-based survey of awareness, testing and treatment of Lp(a) was administered by a medical survey company to clinicians who have been in practice ≥5 years in the US or its territories.

Results

2002 clinicians completed the survey: 47 % were primary care, 35 % cardiology, 9 % endocrinology, and 9 % neurology. 28 % were female, 24 % Asian, 4 % Hispanic, and 3 % Black. Awareness: 81 % of respondents agreed Lp(a) is a significant risk driver for cardiovascular disease (CVD). 77 % and 75 % agreed knowing Lp(a) would help in risk stratification and increase patient engagement, respectively. Testing: 41 % of respondents agreed with universal testing of Lp(a). Most agreed Lp(a) should be measured in those with premature (73 %), family history of premature (71 %), or recurrent CVD events (68 %). Treatment: 77 % reported having CVD outcome data were felt to be very important for a new therapy, followed by long-term efficacy/safety data (69 %), real-world data (53 %), magnitude of Lp(a) reduction (21 %), dosing frequency (17 %), and mechanism of action (12 %). Clinicians reported being most likely to consider prescribing Lp(a)-targeted therapy with proven CVD benefit among patients with premature (47 %) or recurrent (51 %) CVD events.

Conclusion

Most clinicians agree knowing the Lp(a) level can improve risk assessment and patient engagement. Patients with premature or recurrent CVD events are most likely to be targeted for Lp(a) testing and for prescribing possible future Lp(a)-targeted therapies.

Schlagwörter

Stichwörter der Autor:innen

Cardiovascular diseaseDyslipidemiaLipoprotein(a)Prevention

Autor:innen und Institutionen

  • Mary and Steve Wen Cardiovascular Division and Center for Global Cardiometabolic Health and Nutrition, University of California, Irvine.
  • Novartis Pharmaceuticals Corporation.

Förderung

  • Novartis Pharmaceuticals Corporation
  • University of California, Irvine

Zitieren

APA

Wong, N. D., Fan, Y., Fan, W., Ward, J. H., Schludi, B., & Hu, X. (2026). Clinician awareness, testing, and treatment for lipoprotein(a): Results from a large US national survey. American Journal of Preventive Cardiology, 25, 101388. https://doi.org/10.1016/j.ajpc.2025.101388

Vancouver

Wong ND, Fan Y, Fan W, Ward JH, Schludi B, Hu X. Clinician awareness, testing, and treatment for lipoprotein(a): Results from a large US national survey. American Journal of Preventive Cardiology. 2026;25:101388. doi:10.1016/j.ajpc.2025.101388

BibTeX
@article{Wong2026,
  author = {Wong, Nathan D and Fan, Yihang and Fan, Wenjun and Ward, Jonathan H and Schludi, Belinda and Hu, Xingdi},
  title = {Clinician awareness, testing, and treatment for lipoprotein(a): Results from a large US national survey},
  journal = {American Journal of Preventive Cardiology},
  year = {2026},
  volume = {25},
  pages = {101388},
  doi = {10.1016/j.ajpc.2025.101388}
}
Kostenlos starten →